October 17, 2025

Opthea Limited (OPT) Stock Analysis: Navigating the -70.67% Downside Amid Biotech Ambitions

Opthea Limited (NASDAQ: OPT), an Australian biotechnology firm, is at the forefront of developing cutting-edge therapies for ocular conditions. With its core research concentrated on vascular endothelial growth factors (VEGF)..

Standard BioTools Inc. (LAB) Stock Analysis: Is a 37.6% Upside Within Reach for This Healthcare Innovator?

Standard BioTools Inc. (NASDAQ: LAB), a dynamic player in the medical devices industry, has piqued investor interest with a potential upside of 37.6%, according to recent analyst ratings. Based in..

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 472.75% Potential Upside in T Cell Therapy Innovation

Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering player in the biotechnology sector, is capturing investor attention with its innovative T cell therapies aimed at treating cancer and autoimmune diseases. Headquartered..

Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Exploring a Potential Upside of 153.42%

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company nestled in the healthcare sector, is gaining traction among investors intrigued by its promising potential upside. With a market capitalization of $774.22..

Zevra Therapeutics, Inc. (ZVRA)

⚠️ No article content returned.

..

Surmodics, Inc. (SRDX) Stock Analysis: Evaluating Its Position Amid Healthcare Challenges

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector, specifically within the medical devices industry, presents a fascinating case for investors as it navigates complex market conditions. With..

Oric Pharmaceuticals (ORIC) Stock Analysis: A 35% Upside Potential Amidst Strong Buy Ratings

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical-stage biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to combating cancer resistance mechanisms. With a current market capitalization..

AbCellera Biologics Inc. (ABCL) Stock Analysis: A 59.82% Upside Potential Sparks Investor Interest

AbCellera Biologics Inc. (NASDAQ: ABCL), a cutting-edge player in the biotechnology sector, is a company that has caught the attention of investors with its promising 59.82% potential upside. Based in..

Semler Scientific, Inc. (SMLR) Stock Analysis: Unveiling a 205% Potential Upside Amidst Market Volatility

For investors seeking a potentially rewarding opportunity in the healthcare sector, Semler Scientific, Inc. (NASDAQ: SMLR) presents an intriguing case. This medical device company, headquartered in Santa Clara, California, focuses..

Phibro Animal Health Corporation (PAHC): Investor Outlook Highlights Robust Revenue Growth Amid Market Challenges

For investors eyeing the healthcare sector, particularly within the niche of animal health and nutrition, Phibro Animal Health Corporation (NASDAQ: PAHC) presents an intriguing case. With a market capitalization of..

MeiraGTx Holdings plc (MGTX) Stock Analysis: A Biotech Gem with a 236% Upside Potential

MeiraGTx Holdings plc (NASDAQ: MGTX) is capturing significant attention from the investment community due to its promising outlook in the biotechnology industry. With a market capitalization of $654.04 million, MeiraGTx..

CorMedix Inc. (CRMD) Investor Outlook: Analyzing a Potential 103% Upside

CorMedix Inc. (NASDAQ: CRMD), a pioneering entity in the biotechnology sector, has garnered significant investor attention with its ambitious pipeline aimed at addressing life-threatening diseases. As the company stands poised..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 42% Potential Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH) is capturing investor attention with its considerable potential upside of 42.45%, according to analysts’ average target prices. As a biopharmaceutical company, Theravance is dedicated to..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a Biotech Underdog with Nearly 93% Upside Potential

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has emerged as a compelling player in the biotechnology sector, focusing on pioneering gene therapies for rare and life-threatening diseases. With a market capitalization of..

COMPASS Pathways Plc (CMPS): Investor Outlook with a 143% Potential Upside

COMPASS Pathways Plc (NASDAQ: CMPS), a pioneering biotechnology company focusing on mental health treatment, is capturing the attention of investors with its remarkable potential upside of 143.37%. As the company..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Harnessing a 47.67% Potential Upside Amidst Strong Buy Ratings

OrthoPediatrics Corp. (NASDAQ: KIDS), a niche player in the healthcare sector specializing in pediatric orthopedic medical devices, is drawing considerable attention from investors. Despite recent challenges, its significant potential upside..

PureTech Health plc (PRTC) Stock Analysis: Exploring the 162% Potential Upside

PureTech Health plc (NASDAQ: PRTC), a biotechnology company with an intriguing mix of advanced therapeutic candidates, is capturing the attention of investors with its significant potential upside. With a market..

SI-BONE, Inc. (SIBN) Stock Analysis: A Medical Device Innovator with 64% Potential Upside

SI-BONE, Inc. (NASDAQ: SIBN), a leading player in the medical devices sector, has emerged as an intriguing investment opportunity for those seeking high growth potential in the healthcare industry. Specializing..

Cel-Sci Corporation (CVM) Stock Analysis: Is the 1,775% Potential Upside Worth the Risk?

In the dynamic and often unpredictable world of biotechnology, Cel-Sci Corporation (NASDAQ: CVM) presents an intriguing proposition for investors seeking high-risk, high-reward opportunities. With a staggering potential upside of 1,775.16%,..

InnovAge Holding Corp. (INNV) Stock Analysis: What Investors Need to Know About Its Potential Downside

InnovAge Holding Corp. (NASDAQ: INNV), a prominent player in the healthcare sector, particularly in the medical care facilities industry, offers a unique business model that focuses on senior care through..

Search

Funds

October 17, 2025

Search

Funds

October 17, 2025

FTSE 100

Funds